SCHEMBL2471336

SCHEMBL2471336

CC[Hg].[NaH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1310663 0.93
SCHEMBL4431068 0.93
SCHEMBL28334842 0.86
Bromide SCHEMBL160771 0.86
Hydrogen Sulfide SCHEMBL15022782 0.86
Water SCHEMBL11749306 0.86
SCHEMBL4431070 0.86
Hydrochloric Acid SCHEMBL161961 0.86
Iodide SCHEMBL11793013 0.86
Hydrochloric Acid SCHEMBL27863024 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105738300-B Detect kit, method and the purposes of KAPPA light chain content 潍坊三维生物工程集团有限公司 2019-04-30 CN disclosed
CN-107074941-A Bispecific antibody and for ophthalmologic method 豪夫迈·罗氏有限公司 2017-08-18 CN disclosed
CN-105548573-A Kit and method for detecting content of KAPPA light chain and application WEIFANG 3V BIOLOGICAL ENG GROUP CO LTD 2016-05-04 CN disclosed
CN-105548574-A Kit and method for detecting content of C1 inhibitor and application WEIFANG 3V BIOLOGICAL ENG GROUP CO LTD 2016-05-04 CN disclosed
CN-105548571-A Kit and method for detecting content of serum amyloid protein A and application WEIFANG 3V BIOLOGICAL ENG GROUP CO LTD 2016-05-04 CN disclosed
CN-105548572-A Kit and method for detecting content of immune globulin D and application WEIFANG 3V BIOLOGICAL ENG GROUP CO LTD 2016-05-04 CN disclosed
CN-105548575-A Kit and method for detecting content of LAMBDA light chains and application of kit WEIFANG 3V BIOLOGICAL ENG GROUP CO LTD 2016-05-04 CN disclosed
EP-2538781-A2 PROCESS FOR THE CO-ENCAPSULATION OF BIOCIDALLY ACTIVE COMPOUNDS IN CLAY MINERALS FUNCTIONALIZED BY NITROGEN COMPOUNDS Clariant S.A., Brazil (BR) 2013-01-02 EP disclosed
CN-101683310-B Anthranilic acid amides and the derivatives thereof as cosmetic and pharmaceutical agents SYMRISE GMBH AND CO KG 2012-12-12 CN disclosed
WO-2011103969-A2 PROCESS FOR THE CO-ENCAPSULATION OF BIOCIDALLY ACTIVE COMPOUNDS IN CLAY MINERALS FUNCTIONALIZED BY NITROGEN COMPOUNDS CLARIANT S. A. BRAZIL (BR) 2011-09-01 WO disclosed
US-7666436-B1 Pertussis toxin mutants, Bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines NOVARTIS AG (CH) 2010-02-23 US disclosed
US-7427404-B1 Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. (IT) 2008-09-23 US disclosed
CN-1031892-C Expression of human proapolipoprotein A-I UCB SA (BE) 1996-05-29 CN disclosed
EP-0396964-A1 Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines SCLAVO S.p.A. (IT) 1990-11-14 EP disclosed
CN-88103118-A Expression of human Pre-defatted protein A-I 1988-12-14 CN disclosed